Ensysce Biosciences (ENSCW) Other Non Operating Income (2018 - 2025)
Ensysce Biosciences (ENSCW) reported Other Non Operating Income of $17338.0 for Q3 2025, up 18.08% year-over-year from $14683.0 in Q3 2024, and down 17.48% quarter-over-quarter from $21011.0 in Q2 2025.
Ensysce Biosciences (ENSCW) Other Non Operating Income (2018 - 2025) Analysis & Trends
Ensysce Biosciences (ENSCW) has 8 years of Other Non Operating Income data on file, last reported at $17338.0 in Q3 2025.
- Other Non Operating Income for Q3 2025 came in at $17338.0, up 18.08% year-over-year; the trailing twelve-month figure through Sep 2025 was $83918.0 (up 511.89% YoY), and the FY2024 annual result was $17277.0, up 12.04% from the prior year.
- Other Non Operating Income fell to $17338.0 in Q3 2025 per ENSCW's latest filing, from $21011.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $712899.0 in Q2 2021 and troughed at -$61758.0 in Q4 2021.
- A 5-year average of $44550.8 and a median of $8679.0 in 2022 frame the typical range for Other Non Operating Income.
- On a YoY basis, Other Non Operating Income climbed as much as 472.9% in 2024 and fell as far as 736.45% in 2024.
- A 5-year view of Other Non Operating Income shows it stood at -$61758.0 in 2021, then jumped by 208.05% to $66729.0 in 2022, then sank by 111.93% to -$7962.0 in 2023, then soared by 472.9% to $29690.0 in 2024, then slumped by 41.6% to $17338.0 in 2025.
- Business Quant data shows ENSCW's Other Non Operating Income at $17338.0 in Q3 2025, $21011.0 in Q2 2025, and $15879.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Ensysce Biosciences | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 17,338.00 |
| Jun 30, 2025 | 21,011.00 |
| Mar 31, 2025 | 15,879.00 |
| Dec 31, 2024 | 29,690.00 |
| Sep 30, 2024 | 14,683.00 |
| Jun 30, 2024 | 7,394.00 |
| Mar 31, 2024 | -34,489.00 |
| Dec 31, 2023 | -7,962.00 |
| Sep 30, 2023 | 6,934.00 |
| Jun 30, 2023 | 11,030.00 |
| Mar 31, 2023 | 5,419.00 |
| Dec 31, 2022 | 66,729.00 |
| Sep 30, 2022 | 8,679.00 |
| Jun 30, 2022 | 2,850.00 |
| Mar 31, 2022 | 7,966.00 |
| Dec 31, 2021 | -61,758.00 |
| Sep 30, 2021 | 61,758.00 |
| Jun 30, 2021 | 712,899.00 |
| Mar 31, 2021 | -39,585.00 |
| Dec 31, 2020 | 2.23 Mn |